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Abstract  The efficacy of the ACTH 
(4-9) analogue Org 2766 in the pre- 
vention of subclinical cisplatin neu- 
ropathy was assessed in a double- 
blind placebo-controlled multi-centre 
study in patients with testicular can- 
cer or adenocarcinoma of unknown 
primary. Forty-two patients received 
at least four cycles of cisplatin (100 
mg/m 2per cycle), together with sub- 
cutaneous injections of Org 2766 
(2 mg/day for 5 consecutive days) 
or placebo. Vibratory threshold was 
used as a measure of neuropathy. For 
each individual patient, the influence 
of cisplatin on vibratory perception 
was quantified by the slope of the 
regression line between the natural 
logarithm of the vibratory thresholds 
and the number of cycles. From the 
slopes, the proportional increase of 
vibratory threshold per cycle of cis- 
platin was calculated. On average, 
vibratory tresholds increased by 
42% with each cycle of 100 mg/m 2
of cisplatin in the placebo group, 
and by 19% during treatment with 
Org 2766. The influence of cisplatin 
on vibratory thresholds was highly 
significant in the placebo group 
(P < 0.0001), and of borderline 
significance in the group treated 
with Org 2766 (P = 0.06). The dif- 
ference in slopes between the two 
groups was of borderline statistical 
significance (Wilcoxon's two-sample 
test: P = 0.06; analysis of variance: 
P = 0.04). These results show that 
Org 2766 cannot completely prevent 
cisplatin neuropathy in young men 
with testicular cancer, but nerve 
damage may be ameliorated by the 
use of this ACTH (4-9) analogue. 
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Introduction 
Cisplatin is an effective chemotherapeutic agent in the 
treatment of a variety of malignancies, including ovarian 
carcinoma [1], bladder cancer [7], testicular cancer [10] 
and adenocarcinoma of unknown primary tumor [ 12]. The 
main side-effects of cisplatin are nephrotoxicity, myelo- 
suppression, ototoxicity and neuropathy [5, 13]. Cisplatin 
neuropathy is a predominantly sensory peripheral poly- 
neuropathy, often leading to severe sensory and proprio- 
ceptive abnormalities [4]. The neuropathy may continue 
to deteriorate for about 4 months after cessation of treat- 
ment, and is often not completely reversible [6, 8]. Some 
studies indicate that the neuropathy is primarily caused by 
axonal damage of the large myelinated Ia fibres, probably 
at the level of the dorsal root ganglion cell [11]. Others 
suggest hat both demyelination and axonal degeneration 
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occur together [9]. Cl inical neuropathy has been reported 
in at least 50% of patients with ovarian and testicular can- 
cer [2, 10]. The developement of neuropathy is related to 
the total amount of cisplatin received. Subcl inical  oss of 
vibratory sensation in the legs occurs after a cumulat ive 
dose of  350 mg/m 2 [11], while cl inical symptoms usual ly 
develop above a dose of  450-600 mg/m 2 [1, 11]. Above 
200 mg/m 2 per cycle, peripheral neuropathy is considered 
to be the main dose- l imit ing side-effect [5, 11]. 
The ACTH (4-9) analogue Org 2766 has been reported 
to reduce the incidence and severity of  c isplat in- induced 
polyneuropathy in patients treated for ovarian cancer [2]. 
Prel iminary evidence indicates that this neuropeptide 
ameliorates cisplatin neuropathy by enhancing endoge- 
nous nerve repair mechanisms, rather than by protecting 
against he neurotoxic effects of cisplatin [6]. The aim of 
the present double-bl ind trial was to investigate the effi- 
cacy of this ACTH (4-9) analogue versus placebo in pre- 
venting sensory polyneuropathy in patients with metasta- 
tic (non-)seminomatous testicular cancer or adenocarci-  
noma of  unknown pr imary who were treated with cis- 
platin. Vibratory perception has been shown to be a reli- 
able and reproducible indicator of cisplatin neuropathy. 
Elevation of  vibratory thresholds usual ly precedes the oc- 
currence of symptomatic  isplatin neuropathy, and is 
closely related to the severity of  signs and symptoms of  
cl inical ly relevant polyneuropathy [1, 2, 6]. Therefore, the 
vibratory threshold was used as quantitative measure of  
subclinical peripheral sensory polyneuropathy. 
Methods 
Vibratory thresholds were measured at the dorsum of the second 
metacarpal bone of the left hand, with a Vibrameter II! (Somedic 
AB, Stockholm, Sweden), by a method escribed previously [ 1, 2], 
and recorded as micrometres of skin displacement. The Vibrame- 
ter uses a vibratory frequency of 100 Hz and corrects for pressure- 
induced alterations in vibratory amplitude. Age-related normal 
values were obtained from the manufacturer [3]. Vibratory thresh- 
olds were to be obtained before treatment with chemotherapy 
(screening), after the second and fourth cycles and 3-5 months af- 
ter the last cycle. In addition, the presence or absence was noted of 
paraesthesias, numbness, Lhermitte's ign, unsteadiness of gait, 
loss of dexterity and pain [9]. Severity of symptoms i indicated by 
the sum score of positive symptoms (range: 0-6). 
Statistical nalysis 
Patients were considered evaluable if they had been treated with at 
least four cycles of chemotherapy and Org 2766 or placebo, and if 
at least wo vibratory threshold measurements were obtained, after 
two separate cycles of chemotherapy. Some patients received up to 
five additional cycles of chemotherapy, with Org 2766 or placebo. 
For each patient, a linear egression analysis was performed of the 
natural ogarithm of the vibratory thresholds with the number of 
cycles. Because neuropathy may develop for 3-5 months after the 
last cycle [6], values from this period were considered as belong- 
ing to a virtual "last cycle plus one" in the regression analysis. The 
slopes of both patient groups were compared by Wilcoxon's two- 
sample rank sum test and by analysis of variance (ANOVA) with 
correction for age and time intervals between cycles. The signifi- 
cance of the slopes was assessed with the sign test. From the slopes 
of the regression lines, the proportional increase in vibratory 
threshold per cycle of cisplatin was determined. Results were ex- 
pressed as mean (SD), unless indicated otherwise. Two-sided P 
values < 0.05 were considered statistically significant. 
Patients and methods 
Trial design 
The study was a multicentre, double-blind and placebo-controlled 
trial. Patients were treated with cisplatin (20 mg/m 2per day) and 
etoposide, either together or combined with bleomycin or ifos- 
famide ((B)EP or VIP), for 5 days every 3 weeks (mean 21 days, 
SD 5.5 days). The modes of administration f chemotherapy have 
been described previously [10]. Two milligrams of Org 2766 (pro- 
vided by Organon International, Oss, The Netherlands) or placebo 
was subcutaneously injected during the daily courses of chemo- 
therapy. Patients were treated with an intended number of four cy- 
cles, but extended treatment was allowed if necessitated by pro- 
gression of the tumour. 
Patients 
Fifty-five patients were randomized for the study. Patients were re- 
quired to be younger than 60 years; to have no (previous treatment 
of) central or peripheral nervous system metastases; to have no 
signs or symptoms of peripheral neuropathy, orconditions or treat- 
ments known to interfere with the peripheral nervous ystem (e.g. 
diabetes, alcohol abuse); to have no significant abnormalities of
bone marrow, liver or renal function; to have a World Health Or- 
ganisation (WHO) performance status of 2 or better. All patients 
gave informed consent o participate in this trial. The study was 
performed according to the requirements of the Declaration of 
Helsinki. 
Results 
Thirteen of the 55 randomized patients were not evalu- 
able: 11 because fewer than four cycles were administered 
(mostly because of progressive disease), 2 because fewer 
than two neurological  assessments were available. The 
Table 1 Clinical characteristics 
Placebo Org 2766 
Number 23 19 
Male 22 19 
Age (years, range) 28 (1841) 29 (21-52) 
Primary tumour: 
testis 18 16 
unknown 5 3 
Total number of cycles 
of chemotherapy: 
four 18 16 
five-nine 5 3 
Total cumulative amount 
of cisplatin (mg/m 2) 474 (SD 151) 436 (SD 101) 
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Fig. 1 Relative increase (gm) of vibration threshold (VT) per cycle 
clinical characteristics of the remaining 42 patients are 
shown in Table 1. There were no differences between the 
clinical profiles of the two patient groups or in their chemo- 
therapeutic regimens. 
The slope of the relationship between the number of 
cycles of cisplatin and the natural ogarithm of vibratory 
thresholds was 0.27 (0.27) for all 42 patients. There was 
no association between age and slopes (P > 0.80, ANOVA). 
On average, the slopes were considerably larger in the 
placebo group [0.35, (0.28); P < 0.0001 by sign test] than 
in the group treated with Org 2766 [0.17 (0.24); P = 0.06]. 
This indicates that the vibratory threshold increased fol- 
lowing each additional cycle of cisplatin (100 mg/m2), by 
a mean of 42% in the placebo group and by 19% in the 
group treated with Org 2766. The relative increase in vi- 
bratory threshold per cycle of cisplatin is shown in Fig. 1. 
The difference in slopes between the two groups was sig- 
nificant by ANOVA, with correction for age and time in- 
terval between cycles (P = 0.04), but did not reach statis- 
tical significance by Wilcoxon's two-sample rank sum test 
(P = 0.06). 
Subclinical neuropathy can occur at cumulative cis- 
platin amounts of 350 mg/m 2, whereas clinical symptoms 
usually develop above 450 mg/m 2 [1, 11]. Twelve patients 
in the placebo group and 8 patients treated with Org 2766 
received no more than 400 mg/m 2 cisplatin (four cycles) 
and had a vibratory threshold measurement at 3-5 months 
after treatment. The vibratory thresholds in these patients 
are shown in Table 2. Three to 5 months after treatment, 
vibratory thresholds had become abnormal in 9 out of 
these 12 placebo-treated patients (75%) and in 4 of the 8 
patients treated with Org 2766 (50%). 
The average symptom score was 0 out of 6 in both 
groups before treatment. A mean of two symptoms was 
present in the placebo group at 3-5 months after they had 
received four cycles of cisplatin. At this time, patients 
treated with Org 2766 reported one symptom on average 
(not significantly different). 
Table2 Vibratory thresholds (gm) in patients treated with 400 
mg/m 2of cisplatin, combined with placebo r Org 2766 (Pre be- 
fore or after the 1st cycle; > H after the 2nd or 3rd cycle; > IV af- 
ter the 4th cycle; Final 3-5 months after the 4th cycle of cisplatin 
Placebo Org 2766 
[mean (SD)] n [mean (SD)] n 
Pre 0.35 (0.21) 12 0.45 (0.29) 8 
>II 0.41 (0.22) 11 0.40 (0.12) 8 
> IV 0.95 (0.72) 9 0.45 (0.21) 6 
Final 4.03 (5.06) 12 1.85 (1.87) 8 
In the patients treated with more than four cycles of 
cisplatin, vibratory thresholds increased progressively 
during fifth to ninth cycles. During this extended treat- 
ment, vibratory thresholds became abnormal in all 5 pa- 
tients in the placebo group, and in 3 of the 4 patients 
treated with Org 2766. There were no untoward effects of 
treatment with Org 2766. 
Discussion 
The results of the present study show that Org 2766 (10 
mg/cycle) does not completely prevent he increase in vi- 
bratory threshold as occurs in young patients with adeno- 
carcinoma of unknown primary or (non-)seminomatous 
testicular cancer during treatment with cisplatin (100 
mg/m 2 per cycle). There were indications, however, that 
Org 2766 may ameliorate cisplatin-induced polyneuropa- 
thy: vibratory thresholds increased by 19% in patients 
treated with the ACTH (4-9) analogue and by 42% per 
cycle on average in patients treated with placebo. 
These results are in fair agreement with previous clini- 
cal studies of Org 2766 in the prevention of cisplatin-in- 
duced neuropathy in patients with ovarian cancer [2, 6]. In 
these studies, a less than two-fold increase in vibratory 
thresholds occurred during treatment with Org 2766, as 
opposed to a more than eight-fold increase in the placebo 
group, after six cycles of cisplatin [2]. In our study in pa- 
tients with testicular cancer, usually less than six cycles of 
cisplatin were administered. Nevertheless, very similar in- 
creases in vibratory thresholds were derived from the pro- 
portional elevation per cycle of cisplatin: 19% in the Org 
2766-group and 42% in the placebo group amount o a 
2.8-fold and an 8.2-fold increase, respectively, after six 
cycles. The actual values of vibratory thresholds in pa- 
tients treated with four cycles of cisplatin (shown in Table 
2) also suggest hat Org 2766 substantially reduces the 
cisplatin-induced levation of vibratory thresholds. 
The very similar effects of Org 2766 in two different 
groups of patients provide strong indications for a truly 
ameliorating effect of the ACTH (4-9) analogue on cis- 
platin-induced polyneuropathy. The number of clinical 
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signs and symptoms of  neuropathy that developed in this 
study was too low to al low meaningful  statistical analysis. 
In a subgroup of  patients who had received the same cu- 
mulative amount of cisplatin (400 mg/m 2) and who were 
studied within 3-5 months after treatment, patients treated 
with placebo reported twice as many symptoms, on aver- 
age, as patients treated with Org 2766. This suggests that 
Org 2766 may counteract not only subclinical but also 
cl inical ly relevant cisplatin neuropathy, although studies 
in patients with a higher prevalence of c isplat in- induced 
symptoms (e.g. older patients or those receiving higher 
dosages of  cisplatin) wil l  be necessary to demonstrate 
this. 
In summary, our results show that Org 2766, an ACTH 
(4-9) analogue, cannot completely prevent cisplatin-in- 
duced polyneuropathy in young patients with (non-)semi- 
nomatous testicular cancer or adenocarcinoma of  un- 
known primary. This study indicates, however, that this 
neuropeptide can ameliorate cisplatin neuropathy to a de- 
gree that is comparable with effects seen in a previous 
trial of patients uffering from ovarian carcinoma [2]. 
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